Clinical trials: COVID-19 Induced Pneumonia
COVID, Drug Effect
Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Adults With Polypharmacy Using Data From Large Medicare and Commercially Insured Populations
This retrospective study aims to perform a medication risk stratification using drug claims data and to simulate the impact of the addition of various repurposed drugs on the Medication Risk Score (MRS) in a health insurance…
- Conditions
- COVID, Drug Effect, Drug Interaction, Adverse Drug Event
- Trial name
- NCT04378881
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Tabula Rasa HealthCare
Viral Pneumonia, Serotonin Syndrome
Cyproheptadine in Severe COVID-19 : A Unblinded Randomized Trial
This randomized controled open label clinical trial is to evaluate the effect of Cyproheptadine on the clinical course of patients presenting a severe SARS-COV 2 pneumonia.
- Conditions
- Viral Pneumonia, Serotonin Syndrome, Platelet Dysfunction
- Trial name
- NCT04820751
- Testing
- Cyproheptadine Hydrochloride 4 MG
- Volunteers
- 200 people
- Sponsor
- Ciusss de L'Est de l'Île de Montréal
COVID-19, Acute Respiratory Distress Syndrome
Study of Decidual Stromal Cells to Treat COVID-19 Respiratory Failure
This is a research study to see how safe and effective decidual stromal cells are in treating patients with respiratory failure (breathing problem where not enough oxygen is passed from the lungs into the blood) caused by…
- Trial name
- NCT04451291
- Testing
- Decidual Stromal Cells (DSC)
- Where
- 3 sites in Canada
- Volunteers
- 19 people
- Sponsor
- University Health Network, Toronto
COVID-19 Acute Respiratory Distress Syndrome
Prone Positioning and R/I Ratio in COVID-19 Patients With ARDS (SyDRAC-DV)
The purpose of this study is to determine the efects of prone positioning on the recruitment- to-inflation ratio in COVID-19 patients with acute respiratory distress syndrome.
- Trial name
- SyDRAC-DV (NCT05360862)
- Testing
- Prone positioning session
- Where
- France
- Volunteers
- 92 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
SARS-CoV-2, Vaccine
COVID-19 Vaccine Induced Adaptive Immune Responses
The coronavirus disease 2019 (COVID-19) caused by the infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)，resulting in more than 82 million confirmed cases and caused around 1.8 million deaths, as of 2…
- Conditions
- SARS-CoV-2, Vaccine, COVID-19
- Trial name
- NCT04729374
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
COVID-19, ARDS
Respiratory and Hemodynamic Changes Induced in Mechanically Ventilated Patients for COVID-19
In the present context, it seems necessary to try to describe as precisely as possible the physiological alterations due to COVID-19.
- Conditions
- COVID-19, ARDS, Sars-CoV2
- Trial name
- PHYSIO-COVID (NCT04347928)
- Where
- France
- Volunteers
- 15 people
- Sponsor
- University Hospital, Lille
COVID, Drug Effect
Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy
This retrospective study aims to perform a medication risk stratification using drug claims data and to simulate the impact of the addition of various repurposed drugs on the Medication Risk Score (MRS) in elderly people enrolled…
- Conditions
- COVID, Drug Effect, Drug Interaction, Adverse Drug Event
- Trial name
- NCT04339634
- Testing
- Simulation of Repurposed Drugs for COVID-19
- Where
- United States
- Volunteers
- 12,873 people
- Sponsor
- Tabula Rasa HealthCare
SARS-CoV-2 Infection
Study of Specific Viral Immune Responses Induced by SARS-CoV-2 (COVID-19)
SARS-CoV-2, has caused an international outbreak of respiratory illness termed Covid-19. The investigators used peptides derived from SARS-CoV-2 virus, to study viral-specific immune responses.
- Trial name
- COV-CREM (NCT04365322)
- Testing
- Additional biological samples
- Where
- France
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Besancon
COVID-19
Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment
Aerosol Combination therapy of All-trans retinoic acid and Isotretinoin as A novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients better than vaccine : An innovative Treatment Mahmoud…
- Trial name
- Antibodies (NCT04396067)
- Testing
- Aerosolized 13 cis retinoic acid, Aerosolized All trans retinoic acid
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Kafrelsheikh University
Covid19, Thrombotic Microangiopathies
Ravulizumab and COVID-19
Ultomiris (Ravulizumab), is a monoclonal antibody that specifically targets terminal complement products and is proposed for the treatment of COVID-19 induced microvasculature injury and endothelial damage leading to thrombotic…
- Conditions
- Covid19, Thrombotic Microangiopathies, Acute Kidney Injury
- Trial name
- NCT04570397
- Testing
- Ravulizumab
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Brigham and Women's Hospital
COVID-19, ARDS
Assessment of Analgesics and Sedatives in Mechanically Ventilated Patients With COVID-19
The analgesic and sedation requirements in critically ill patients with COVID-19 have yet to be described. There are various factors that are likely affecting the agents being utilized for analgesia and sedation in these patients…
- Conditions
- COVID-19, ARDS, Withdrawal Syndrome, Iatrogenic Disease
- Trial name
- NCT05336656
- Where
- United States
- Volunteers
- 353 people
- Sponsor
- Wilkes University
Covid19, Pneumonia
Intravenous Immunoglobulin (IVIG, Bioven) Efficacy Assess for COVID-19 / SARS-CoV-2 Severe Pneumonia Complex Treatment
Pneumonia caused by coronavirus infection COVID-19 is characterized by a combination of several dangerous factors that consistently worsen the patient's condition: viral lung damage early in the disease; a sharp increase in…
- Trial name
- NCT04500067
- Testing
- IVIG
- Where
- 9 sites in Ukraine
- Volunteers
- 76 people
- Sponsor
- Biopharma Plasma LLC
COVID-19 Infection
DISmantling COvid iNduced Neutrophil ExtraCellular Traps (DISCONNECT-1)
This is a pilot study to investigate the safety and feasibility of rhDNase1 and its impact on neutrophil extracellular traps (NETs) in COVID-19 infected patients.
- Trial name
- DISCONNECT-1 (NCT04409925)
- Testing
- rhDNase I
- Where
- 2 sites in Canada
- Volunteers
- 15 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
COVID, Coronavirus
Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization
Our overarching goal is to improve the outcomes of critically ill COVID-19 patients with or at risk for development of acute kidney injury (AKI).
- Conditions
- COVID, Coronavirus, Coronavirus Infection, AKI
- Trial name
- NCT04530448
- Testing
- Sodium bicarbonate, Standard of Care
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- West Virginia University
Sars-CoV2, Acute Respiratory Distress Syndrome
Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)
*At this time, we are only enrolling at Houston Methodist Hospital (HMH)/Baylor College of Medicine (BCM) and are not shipping cells outside of BCM/HMH.* This is a study for patients who have respiratory infection caused by…
- Conditions
- Sars-CoV2, Acute Respiratory Distress Syndrome, COVID-19
- Trial name
- NCT04345601
- Testing
- Mesenchymal Stromal Cells, Supportive Care
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Baylor College of Medicine
Anxiety and Fear, Anxiety Depression
Psychological Well-being of Patients Awaiting for Cardiac Surgery During the COVID-19 Pandemic
The effect and impact of postponing cardiac surgery / creating a waiting list as a result of COVID-19 on patients, both psychologically and symptomatically on three groups of patients: 1.
- Conditions
- Anxiety and Fear, Anxiety Depression, Anxiety Postoperative, Psychological Stress
- Trial name
- NCT04406181
- Testing
- HADS, a survey
- Where
- Belgium
- Volunteers
- 200 people
- Sponsor
- Universitair Ziekenhuis Brussel
SARS-CoV-2 Infection
Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)
The mortality rate of the disease caused by the corona virus induced disease (COVID-19) has been estimated to be 3.7% (WHO), which is more than 10-fold higher than the mortality of influenza.
- Trial name
- CORON-ACT (NCT04335071)
- Testing
- Tocilizumab (TCZ)
- Where
- 4 sites in Switzerland
- Volunteers
- 5 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Anxiety Depression, Alcohol Abuse
CBD Oil for Reducing Emotional Impact of COVID-19
Our purpose is to conduct a 4-arm placebo-controlled clinical trial to investigate the relative clinical efficacy of 300 mg. of pure hemp-derived CBD isolate, 300 mg. of full spectrum CBD oil, 300 mg.
- Conditions
- Anxiety Depression, Alcohol Abuse, Substance Abuse, Anger
- Trial name
- CBDOIL (NCT04603781)
- Testing
- CBD Isolate, Full Spectrum CBD Oil, Broad-Spectrum CBD Oil
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Texas at Austin
Covid19
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory Distress
This is a Phase 2 study to assess COVI-MSC in the setting of current standard of care in hospitalized subjects with RT-PCR confirmed SARS-CoV-2 (COVID-19) infection and acute respiratory distress / acute respiratory distress…
- Trial name
- NCT04905836
- Testing
- COVI-MSC
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- Sorrento Therapeutics, Inc.
Covid19, Acute Respiratory Distress Syndrome
The MEseNchymal coviD-19 Trial: MSCs in Adults With Respiratory Failure Due to COVID-19 or Another Underlying Cause
This is a pilot, multi-centre, open-label randomised controlled study to assess the early efficacy of intravenous (IV) administration of CYP-001 in adults admitted to an intensive care unit (ICU) with respiratory failure
- Trial name
- MEND (NCT04537351)
- Testing
- CYP-001
- Where
- 5 sites in Australia
- Volunteers
- 14 people
- Sponsor
- Cynata Therapeutics Limited